Conference Coverage

VIDEO: CASTLE-AF suggests atrial fibrillation burden better predicts outcomes

View on the News

AF ablation succeeds despite recurrences

This new analysis of data from the CASTLE-AF trial is exciting. It shows that, if we reduce the atrial fibrillation burden when we perform catheter ablation of atrial fibrillation in patients with heart failure, patients do better.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Until now, cardiac electrophysiologists who perform atrial fibrillation (AF) ablation have been too hard on themselves by counting as a failure every patient who develops an AF recurrence that lasts for 30 seconds or more. We know that patients who have a substantial drop in their AF burden after catheter ablation report feeling better even if they continue to have some AF events. When their AF burden drops substantially, patients are better able to work and perform activities of daily life. Many options, including noninvasive devices, are now available to monitor patients’ postablation change in AF burden.

We currently tell patients the success rates of catheter ablation on AF based on recurrence rates. Maybe we need to change our definition of success to a cut in AF burden. Based on these new findings, patients don’t need to be perfect after ablation, with absolutely no recurrences. I have patients who are very happy with their outcome after ablation who still have episodes. The success rate of catheter ablation for treating AF may be much better than we have thought.

Andrea M. Russo, MD , is professor and director of the electrophysiology and arrhythmia service at Cooper University Health Care in Camden, N.J. She made these comments during a press conference and in a video interview. She had no relevant disclosures.


 

REPORTING FROM HEART RHYTHM 2018


CASTLE-AF was sponsored by Biotronik. Dr. Brachmann has been a consultant to and has received research funding from Biotronik and several other companies. Dr. Krahn has been a consultant to Medtronic and has received research support from Medtronic and Boston Scientific. Dr. Link had no disclosures.

SOURCE: Brachmann J et al. Heart Rhythm 2018, Abstract B-LBCT02-04.

Pages

Recommended Reading

MDedge Daily News: Which diabetes drug boosts survival best?
MDedge Cardiology
Women’s representation in CV drug trials still lagging
MDedge Cardiology
First reversal agent for apixaban and rivaroxaban gets fast-track approval
MDedge Cardiology
Adding vasopressin in distributive shock may cut AF risk
MDedge Cardiology
Novel targeted cancer drugs cause fewer arrhythmias
MDedge Cardiology
Thirty-second atrial fib threshold may drive overdiagnosis
MDedge Cardiology
Implanted pulse generator ups exercise tolerance in HF
MDedge Cardiology
CABANA: AF ablation ties drug management, with an asterisk for crossovers
MDedge Cardiology
To detect subclinical AF, insertable monitor is unequaled
MDedge Cardiology
Heart rate variability may be risk factor for depression, not a consequence
MDedge Cardiology